US protection

US protection ending in 2029: Mental health

As of the edition of 20 October 2026, 17 drugs have US protection that ends in 2029 in mental health; 10 of them have at least one company on route B because of it.

Sources: FDA Orange Book and Purple Book, other approval registers.

17 drugs

DrugUS protectionStatusHolderTargetRoute B rows
Abacavir Ends 2029 (patent)Marketed GSK 0
Atazanavir Ends 2029 (patent)Marketed Bristol Myers Squibb 0
Budesonide Ends 2029 (exclusivity)Marketed NR3C1 5
Cariprazine Ends 2029 (patent)Marketed AbbVie DRD2, DRD3 4
Dapagliflozin Ends 2029 (patent)Marketed AstraZeneca SLC5A2 2
Edaravone Ends 2029 (exclusivity)Marketed Shionogi 0
Eluxadoline Ends 2029 (patent)Marketed AbbVie OPRM1 1
Etonogestrel Ends 2029 (exclusivity)Marketed Organon PGR 1
Ferric derisomaltose Ends 2029 (patent)Marketed Pharmacosmos TF 2
Florbetaben Ends 2029 (patent)Marketed Lantheus Biosciences 0
Ganaxolone Ends 2029 (exclusivity)Marketed Immedica Pharma 0
Linaclotide Ends 2029 (exclusivity)Marketed AbbVie GUCY2C 3
Lumateperone Ends 2029 (patent)Marketed Johnson & Johnson DRD2, HTR2A, SLC6A4 1
Phenobarbital Ends 2029 (exclusivity)Marketed SUN Pharmaceutical Industries 0
Suvorexant Ends 2029 (patent)Marketed Merck & Co. HCRTR1, HCRTR2 2
Trazodone Ends 2029 (patent)Marketed Pragma Pharmaceuticals HTR2A, HTR2C 1
Varicella zoster virus envelope glycoprotein e Ends 2029 (computed from the first US licence)Marketed GSK 0

Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.

Which companies are on route B in 2029 in mental health

In the product

10 of these 17 drugs have at least one company on route B. Which companies, and their scores, are in the product.

Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.

US protection movers, once a month

The drugs that entered or left the two-year window in the latest edition. An email, not an account: it gives no access to the product.